Dr Reddys enters into licensing agreement for ophthalmic product for US market

30 Jul 2022 , 11:59 AM

Dr Reddys Laboratories has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC (?Slayback?), to acquire rights in Slaybacks Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify? in U.S. Lumify? is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddys exclusive rights to the product outside the U.SPowered by Capital Market – Live News